Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

iShares S&P GSCI Commodity-Indexed Trust ETFTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

iShares S&P GSCI Commodity-Indexed Trust ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $36.18 (market cap $1.02B), while Recursion Pharmaceuticals Inc trades at $3.93 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2.1× iShares S&P GSCI Commodity-Indexed Trust ETF's market cap, and iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares S&P GSCI Commodity-Indexed Trust ETF for 41 Days and Recursion Pharmaceuticals Inc for 22 Days on average.

GSGRXRX
Market Cap
$1.02B$2.14B
Volume
1,256,22130,789,535
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$37.15$6.79
52-Week Low
$22.45$2.84
Typical Hold Time
41 Days22 Days
Enterprise Value
—$1.66B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares S&P GSCI Commodity-Indexed Trust ETF

No Aura AI signal available yet.

Recursion Pharmaceuticals Inc

RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.

The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GSG
0% Buy100% Sell
Avg holding period · 41 Days
RXRX
8% Buy92% Sell
Avg holding period · 22 Days

About iShares S&P GSCI Commodity-Indexed Trust ETF

GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.

Read more on GSG →

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX →